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ABSTRACT 
For 60-plus years the explanatory model for Major Depressive Disorder (MDD) has been 
the monoamine theory, which states that low levels of monoamine neurotransmitters or 
alterations in their post-synaptic receptors are responsible for depressive symptoms. Drugs 
designed to elevate synaptic monoamine levels have remained the first line of pharmacotherapy 
prescribed by clinicians for MDD patients. However, these drugs have shortcomings. Despite 
evidence that current antidepressants elevate synaptic monoamine levels within hours of 
administration, these drugs require four to six weeks of daily administration before symptom 
relief appears. Furthermore, approximately half of patients taking typical antidepressants never 
achieve full symptom relief. The therapeutic lag time and low response rates associated with 
typical antidepressants suggests that elevation of monoaminergic activity may not be their true 
mechanism of antidepressant action and brings into question the validity of the monoamine 
theory. As a result, novel biological targets have been investigated for development of more 
reliable and faster-acting antidepressants. Recent work has shown that low doses of ketamine, a 
glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonist, can provide depressive 
symptom relief within hours of administration. What is interesting about these findings is that 
ketamine works on a completely different biological system than typical antidepressants. 
Moreover, a number of non-drug treatments, such as electro-convulsive therapy, 
psychotherapies, and exercise have proven efficacious in treating depressive symptoms. 
Understanding the biological mechanisms that underlie all of these various treatment modalities 
may provide evidence for a more valid explanatory model of MDD. In a review of relevant 
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literature examining biologic alterations produced by monoaminergic antidepressants, ketamine 
and other glutamatergic agents, psychotherapies, electroconvulsive shock therapy, or exercise a 
commonality was identified: all of the treatments promote the growth of new synapses 
(synaptogenesis) and the growth of new neurons (neurogenesis). This finding prompts support 
for the developing Stress-Neurogenic Theory of depression. This theory suggests depressive 
symptoms are due to chronic, unpredictable stressors which stimulate the production of stress 
hormones leading to cell death in major brain areas and treatment for depression is dependent 
upon stimulating the brain’s natural processes responsible for the growth of new connections and 
new cells in affected brain regions.  
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1.0 INTRODUCTION 
 
 According to the National Institute of Mental Health, major depressive disorder (MDD), 
or major depression, is characterized by a combination of symptoms that interfere with a 
person’s ability to work, sleep, study, eat, and enjoy once-pleasurable activities. Some people 
may experience only a single depressive episode within their lifetime, but more often a person 
will experience multiple depressive episodes.  According to the DSM-5, five of the following 
criteria must be met in the same two week period to diagnose someone as suffering from a major 
depressive episode:  1) depressed mood most of the day, nearly all day;  2) diminished interest or 
pleasure in all, or almost all activities most of the day nearly every day;  3) significant weight 
loss when not dieting or significant weight gain, or a decrease or increase in appetite nearly 
every day;  4) insomnia or hypersomnia nearly every day;  5) psychomotor retardation or 
agitation nearly every day;  6. Fatigue or loss of energy nearly every day;  7) feelings of 
worthlessness or excessive or inappropriate guilt nearly every day;  8) diminished ability to think 
or concentrate, or indecisiveness, nearly every day;  9) recurrent thoughts of death other than fear 
of death, recurrent suicidal ideation, or a suicide attempt, or a specific plan for committing 
suicide (Diagnostic and Statistics Manual-5).   
A 2003 study using 9090 participants found that 16.2% suffered from an MDD episode 
during their lifetime and that 6.6% of the participants experienced a major depressive episode
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 during the 12 months before the study.  If those sample numbers were extrapolated to the 
general population, the study suggests that between 33-35 million U.S. adults experience a major 
depressive episode in their lifetime and between 13-14 million U.S. adults experience at least one 
depressive episode during a 12-month period (Kessler et al, 2003).  In a 2005 follow up study 
designed to estimate 12- month prevalence, severity, and comorbidity of DSM-IV anxiety, mood, 
impulse control, and substance abuse disorders found that 6.7% of the subjects experienced a 
major depressive episode in the preceding 12 months, findings consistent with the 2003 study 
(Kessler et al., 2005).  The estimated economic cost of MDD in 2000, which includes the cost of 
treatment and loss of work productivity, was estimated at $83.1 billion in the United States alone 
(Greenberg et al. 2003).  
While the economic impact of MDD is staggering, major depressive disorder is not the 
only type of depressive disorder. Other common depressive subtypes are treatment-resistant 
depression, bipolar depression, and dysthymic disorder. Although it is not recognized by the 
Diagnostic Statistical Manual (DSM) used by clinicians for diagnosis of mental disorders, 
treatment- resistant depression, or TRD, is relatively common in MDD cases as only 50% of 
MDD patients respond to typical pharmacotherapies for depression (Papakostas, G. I., & Fava, 
M. 2010). Currently the FDA defines treatment-resistant depression as the failure of depressed 
patients to respond to adequate dosing and regimen of pharmacotherapies from two distinct 
classes of traditional antidepressants. This diagnostic criteria can only be made post-treatment 
thus leaving patients to continue to suffer from depressive symptoms. A 2010 study by Fostick 
and colleagues revealed that patients diagnosed with TRD suffer from more severe MDD 
symptoms as scored on the Hamilton Depression Rating Scale (HDRS).  In this study 107 
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patients diagnosed with MDD were interviewed by a psychiatrist who was blind to the purpose 
of the study and to the treatment history of the patients and scored the severity of depressive 
symptoms using the HDRS.  The study reported that non-TRD patients had a mean score of 9.8 
versus a mean score of 18.6 for TRD patients (Fostick et al., 2010).  This same study also found 
a positive correlation between depression severity and economic impact. Patients with more 
severe depression had increased direct costs, such as blood and imaging tests, physician visits, 
and hospitalization costs, as well as increased indirect costs, such as lower worker productivity 
and higher worker absenteeism.  In a recent meta-analysis of the cost of MDD patient care from 
2001 to 2009, it was found that the medical expenses for TRD patients was almost 30% higher 
than normal MDD patients (Olchanski et al., 2013). The association of increased expenses and 
TRD was confirmed in an analysis by Gibson and colleagues who found that, on average, 
depressed patients deemed treatment resistant had 40% higher medical costs compared to 
respondent MDD patients (Gibson T. et al., 2010).  
While the economic impact of depressive disorders is significant, not only to the sufferer 
but to the general public as well, the more troubling symptom of these depressive disorders is 
suicide ideations and attempts. According to the Center for Disease Control (CDC) website, 
suicide is defined as “death caused by self-directed injurious behavior with intent to die as a 
result of the behavior.” (see www.cdc.gov). The CDC also lists suicide as the tenth leading cause 
of death in 2015 and the third leading cause of death among people between the ages of 10 and 
14 and the second leading cause of death among people between the ages of 15 and 34 in that 
same year. Furthermore, the CDC reports that there were 44,193 suicides in 2015 compared to 
17,793 homicides.   
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The economic and personal impact of depressive disorders make the need for effective 
therapies for MDD paramount. Identifying and developing more effective and faster acting 
antidepressants requires our full understanding of the etiopathology associated with the disorder. 
The purpose of this paper is to review the development of the monoamine theory of depression, 
examine the validity of the findings that prompted it, and identify any common mechanisms 
shared by all forms of efficacious treatment for depression. If any commonality in biological 
alterations exists between the various treatment modalities, it may prove useful in developing a 
more valid explanatory model for MDD, which would promote a new avenue in development of 
more effective and faster acting antidepressant pharmacotherapies.    
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2.0 BACKGROUND 
 
 
2.1: Development of the Monoamine Theory of MDD 
 
 
 For the past 60-plus years, the etiology of MDD has been explained through the 
monoamine theory which proposes that MDD is caused by deficiencies in the monoaminergic 
neurotransmitters, specifically serotonin (5-HT) and norepinephrine (NE), or by some 
dysregulation of their post-synaptic receptors. Evidence in support of this theory originates from 
two discoveries that occurred in the 1950’s: 1) the ability of drugs that elevate monoaminergic 
activity to improve mood and 2) drugs that deplete synaptic monoamine levels induce 
depression.  
 Prior to the 1950’s, the use of electro-convulsive shock therapy (ECT) developed by Ugo 
Cerletti was the most successful treatment option for depressive disorders, but due to the 
invasiveness of the procedure, it was only used as a last resort after traditional therapist-client 
psychiatric methods failed.  The development of the first pharmacotherapies for depression in the 
1950’s occurred by chance. In 1951, pre-clinical researchers began investigating the anti-
tuberculosis properties of a class of compounds called hydrazines. After testing in animals 
proved successful, clinical trials with the most promising hydrazine, isoniazid, took place in 
hospitals across the state of New York. The antitubercular effects on isoniazid in these hospitals 
offered hope for patients, doctors, and researchers and opened an avenue for the development of 
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structurally similar drugs, such as iproniazid which was much more effective in humans than 
isoniazid. As a side note of interest, introduction of these drugs to treat tuberculosis caused the 
death rate in the United States to fall from 188 deaths per 100,000 persons in 1904 to just 4 in 
1952. In that same year, doctors using iproniazid to treat tuberculosis patients at Sea View 
Hospital on Staten Island in New York noticed that tubercular patients treated with iproniazid 
showed increased vitality and an increase in their social interactions with other patients and staff 
and even led to some patients engaging in dancing in the hospital, the event immortalized in the 
picture “The Patient’s Dance.” (see image below).  
 
Image 1: Tubercular patients at Sea View Hospital dancing after treatment with hydrazines. 
 
 However, these behavioral changes were seen as side effects assumingly produced by 
iproniazid’s stimulatory effects to the central nervous system and were not initially recognized 
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by the doctors as alterations to patients’ mood. In an effort to determine exactly how these 
hydrazines worked biologically, in 1952 a team at Northwestern Medical School in Chicago 
discovered that iproniazid was more effective than isoniazid at inhibiting monoamine oxidase 
(MAO), the enzyme responsible for enzymatic degradation of the monoamine neurotransmitters 
dopamine, norepinephrine, and serotonin. As a result of inhibiting this enzyme, iproniazid 
increases the amount of the monoamine neurotransmitters in the synaptic cleft and thus increases 
the activation of their post-synaptic receptors. In 1957, researchers at the National Institute of 
Health (NIH) led by Sydney Udenfriend observed that administration of iproniazid, but not 
isoniazid, in animals resulted in rapid elevation in brain levels of the monoamine 
neurotransmitter serotonin, an important discovery in iproniazid’s effect on the central nervous 
system. These findings led to iproniazid being the favored choice in trials for anti-tubercular 
properties. 
 However, iproniazid was eventually abandoned as a treatment option for tuberculosis due 
to a poor safety profile, except in extreme cases, though some researchers concluded that the 
stimulatory side effects of iproniazid could be a primary effect if used as treatment for certain 
psychiatric disorders. Researchers and practitioners in the United States began to use and report 
the mood altering effects of the hydrazine compounds isoniazid and iproniazid. In 1952, Jean 
Delay reported that two out of four patients (50%) treated with isoniazid showed depressive 
symptom improvements (Delay, Lainé, & Buisson, 1952).  In 1953 a two to three week trial with 
iproniazid in 11 psychiatric patients suffering from various disorders reported that two of the 11 
(18%) “appeared improved” in opinion of themselves, interest in general activity in the ward, 
and general appearance (Smith, 1953). And also in 1953, Salzer and Lurie used isoniazid to treat 
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a group of 40 depressed patients and reported that approximately 70% showed improvement in 
mood (Salzer and Laurie, 1953). In the publication of findings from this last study, the 
psychiatrist Max Lurie, a private practice psychiatrist in Cincinnati, along with Harry Salzer first 
used the term “antidepressant” to describe the mood enhancing effects of the hydrazine isoniazid 
in depressed patients. 
 Together, the discovery of the hydrazine’s effect on mood and their biological 
mechanism of action (inhibition of monoamine oxidase resulting in increased synaptic activity of 
the three monoamines) was an important step in developing a biological explanation for 
depression. The second piece of evidence in the development of the monoamine model of 
depression came from reserpine’s ability to induce depressive states. Reserpine is the primary 
active compound from the Indian snakeroot plant (rauwolfia serpentine) and is capable of 
blocking the storage of monoamines into vesicles in the pre-synaptic terminal. By blocking the 
vesicular monoaminergic transporter (VMAT), reserpine reduces the amount of monoamine 
neurotransmitters stored in presynaptic vesicles. While normal exocytosis processes remain 
uninterrupted, the vesicle is empty and releases very little, if any, monoamines into the synapse, 
thus reducing activity at their post-synaptic receptors. The behavioral and physiological effects 
of reserpine had long been known to the people of India. It was commonly used to treat snake 
bites, provide a calming effect to infants and mental patients, and was later determined to lower 
blood pressure and was marketed as an antihypertensive drug in India in the 1930’s. Reports 
from India on the use of Rauwolfia and/or its primary compound reserpine in calming patients 
with mental disorders prompted its trial in treating schizophrenic patients at Rockland State 
Hospital in New York in 1954. While it failed to provide psychotic symptom relief, it was noted 
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to produce behavioral sedation as measured by a reduction in both assaults and the need for 
patient restraint (Kline, N., 1954). However, reserpine still proved useful in treating hypertension 
and a number of early trials in patients suffering from psychiatric illnesses and/or hypertension 
reported reserpine’s depressionogenic effects (Fries E., 1954; Harris T., 1957).   
 Together, the two discoveries 1) that early anti-tubercular drugs improved mood and 
elevated synaptic monoamine levels and 2) that reserpine reduces synaptic monoamine levels 
and is depressionogenic, led to the development of the Monoamine Theory of Depression. 
 Today there are a number of different classes of drugs that increase synaptic 
monoaminergic activity through various mechanisms. As described above, early antidepressants 
attempted to increase synaptic monoamine levels by inhibiting their enzymatic degradation via 
monoamine oxidase (i.e. monoamine oxidase inhibitors or MAOI’s), thus prolonging 
monoamine availability in the synapse and increase activity on their post-synaptic receptors. 
However, MAOI’s proved to have potentially deadly dietary interactions and have fallen out of 
use. More recent drugs utilized to treat MDD comprise three separate classes of drugs, each with 
its own mechanism of action of increasing synaptic levels of serotonin and/or norepinephrine and 
include 1) tricyclic inhibitors (TCA’s) of both NE and 5-HT reuptake transporters, such as 
imipramine, 2) selective serotonin reuptake inhibitors (SSRI's), such as fluoxetine, and 3) newer 
selective NE reuptake inhibitors (SNRI's), such as maprotiline.  However, the Monoamine 
Theory of MDD and the drugs designed to treat depression based on that theory are not without 
their issues.  
 Firstly, the monoamine theory of depression was “accidentally” discovered. The mood 
enhancing effects of the hydrazine antidepressants were initially mistaken for simple stimulatory 
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effects on the nervous system. Through some sharp clinical observation, some researchers 
proposed that these side effects could be considered primary effects in a different population of 
patients.  However, the early clinical trials with hydrazines reported only modest 
“antidepressant” effects in patients with response rates varying between 18 to 70% (cited above).  
These findings were a major underpinning of the monoamine theory, however, they are not 
without their criticisms. In evaluating these studies, we should consider the criteria the 
researchers were using for their diagnosis of depression. The major diagnostic tool during the 
time these studies took place was the DSM-I, published in 1951 and prior to its publishing, there 
were a number of different references offering differing diagnostic criteria for depression. In the 
DSM-I, affective disorders such as depression were grouped under the larger category of 
“Psychoneurotic Reactions,” with the cause of such disorders attributed to two factors: 1) 
“psychogenic” factors such as those proposed under the Freudian theories of unresolved 
unconscious conflicts, and 2) some undefinable and intangible structural change (i.e. unknown 
biological alterations). The DSM-I does not actually list any direct symptoms of depression, or 
Depressive Reactions, but instead gives a general description of overall depressive behavior 
attributing it to recent losses in the patient’s life and/or some sense of guilt being experienced by 
the patient. The limited description of depressive symptoms given in the first edition of the DSM 
brings into question the validity of diagnoses made in early patients, and thus early clinical trials. 
It also brings into question the validity of how “antidepressant” effects were measured in patients 
in these early trials. For example, the clinical study performed by Smith in 1953 proposed that 
improvements or increases in self-opinion, curiosity of hospital activities, and personal hygiene 
as evidence for iproniazid’s antidepressant effects. While changes in these behaviors were 
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certainly an improvement for patients, are they truly representative of a positive change in 
mood? 
 Another issue with these findings lies in the research methodology employed in these 
early clinical studies.  None of them report using any kind of control group for comparison, nor 
report any blind procedures but instead measure improvement via researcher observations. Lack 
of control in these studies suggest the possibility of a placebo effect in patients not blinded to 
experimental design and the possibility of researcher bias in the interpretation of behavioral 
changes/improvement in non-blinded observers, both of which are a huge concern in 
antidepressant trials.  In an analysis of clinical trials with monoaminergic antidepressants in the 
years between 1985 and 1997, Khan and Brown found that investigator and rater bias influenced 
the magnitude of symptom reduction in these studies, reporting the following on the difference 
between monoaminergic antidepressants and placebo: 
 “Specifically, it became evident that the magnitude of symptom reduction was about 40% 
with antidepressants and about 30% with placebo.” (Khan and Brown, 2015).   
 Additionally, the authors found that evaluators of depression symptoms graded a higher 
magnitude of effect for antidepressants in non-blind trials compared to antidepressant effects in 
blinded trials.  While the analysis by Khan and Brown did not directly analyze the early clinical 
trials with hydrazines, the lack of proper controls in those early trials suggest their results may 
have also been influenced by observer/researcher biases and/or the placebo effect. These factors 
cast doubt on one of the pillars that served as the basis of the monoamine theory. 
 The other pillar in the development of the monoamine theory of MDD was the 
depressionogenic effects of reserpine. As detailed above, reserpine’s mechanism results in a 
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depressed mood state by reducing synaptic monoamine levels. However, the early studies 
demonstrating reserpine’s effect on mood were also flawed. The trials conducted by Freis in 
1952 and Harris in 1957 included patients suffering from chronic illnesses and/or hypertension. 
Depression rates among the chronically ill are very high (approximately 50% according to Bant, 
1978). Depression thought to be caused by reserpine in chronically ill patients could be 
misattributed to the drug instead of being attributed no normal rates of depression within that 
specific population. Furthermore, the depression rates for hypertension patients that were taking 
reserpine was reported at approximately 10% (Baumeister et al., 2003). If you recall from the 
introduction in this paper, a 2003 study by Kessler et al. found that approximately 6.6% of the 
general population suffered from a depressive episode within the prior 12 months leading up to 
the study.  Comparison of these statistics imply only a marginal increase in depression rates 
among hypertension patients taking reserpine. Combined, these issues suggest that reserpine may 
not actually be depressionogenic.  
Finally, current antidepressants developed based on the monoamine theory have some 
serious limitations.  These drugs, as a whole, possess numerous undesirable side effects 
including dizziness, constipation, hypertension and other cardiac issues, and sexual dysfunctions. 
While it has been demonstrated that monoaminergic antidepressants are capable of elevating 
synaptic monoamine levels within hours after administration, four to six weeks of daily drug 
administration is needed to produce adequate MDD symptom relief (Paul & Skolnick, 2003; 
Trivedi, Rush, Wisniewski, 2006). Moreover, not all MDD patients show depressive symptom 
alleviation following monoaminergic antidepressant use.  It is reported that between 40 to 60% 
of MDD patients fail to see depressive symptom relief following adequate regimens of typical 
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antidepressants (Paul, Skolnick, 2003; Trivedi, Rush, Wisniewski, 2006) resulting in roughly 
half of all MDD patients undergoing treatment with typical antidepressants being diagnosed with 
TRD.  
The moderate response rate and lag time of therapeutic effects from drugs targeting 
monoaminergic systems suggests that increased synaptic monoaminergic levels are not sufficient 
for depressive symptom relief and brings into question the validity of the monoamine theory of 
depression. If these drugs elevate synaptic monoamine levels within hours, why does it take 
weeks before depressive symptom relief appears? And if the Monoamine Theory of depression is 
a valid explanatory model, why do only half of people who take current antidepressants show 
symptom relief/remission? These treatment shortcomings suggest that the true therapeutic 
mechanism of current antidepressants may be some other downstream process or processes that 
are eventually achieved as a result of the increases in monoamine activity produced by 
antidepressants, and not their direct and immediate influence on monoaminergic neurotransmitter 
levels. In a review of the mechanisms of antidepressants and their effects, while commenting on 
the mechanism of tricyclic antidepressants, Andrade and Rao explained it in these terms:  
“A fundamental problem with the synaptic explanations described above is that, while 
they are immediate, the antidepressant response is delayed. For example, the TCA’s inhibit the 
reuptake of monoamines as soon as they are absorbed into the body and transported across the 
blood-brain-barrier, i.e. within hours of administration. However, the antidepressant response 
takes weeks or longer to develop and complete and, hence, for response and remission to occur. 
Therefore to say that the TCA’s act by increasing the presence of neurotransmitters in the 
synapse is about as complete as saying that cars run because of an increased presence of fuel in 
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the tank. Clearly, just as mechanisms downstream to the presence of fuel in the tank enable a car 
to move, so too must there be something downstream to increase the synaptic availability of 
monoamines to fully explain antidepressant mechanisms.” (Andrade and Kumar Rao, 2010).   
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2.2: Secondary Effects of Monoaminergic Antidepressants 
 
Numerous preclinical studies report that many of the conventional monoaminergic 
antidepressants have a number of secondary biological effects. For example, typical 
antidepressants increase neurotrophic growth factors, such as brain-derived neurotropic factor 
(BDNF) (reviewed in Altar, 1999). These growth factors are responsible for neuronal survival, 
synaptogenesis, and neurogenesis.  Chronic administration of representative compounds from 
monoaminergic antidepressant classes have been shown to increase the required genetic 
precursor, messenger ribonucleic acid (mRNA), which codes for BDNF production (Nibuya, 
Morinobu, Duman, 1995; Fujimaki et al., 2000 de Foubert, et al., 2004; Reagan, et al., 2007). 
Additionally, in the study cited above by Reagan and colleagues, the researchers measured 
increases in BDNF protein levels themselves in several major brain regions implicated in the 
pathology of MDD following chronic administration of monoaminergic antidepressants.  
Interestingly, de Foubert and colleagues reported that chronic administration (21 days) but not 
acute administration of the SSRI fluoxetine (Prozac) was required to produce an increase in 
BDNF mRNA levels, a time course similar to the requirements for the antidepressant effects of 
fluoxetine and other monoaminergic-based drugs seen in MDD sufferers (4 – 6 weeks).  
Furthermore, pre-clinical trials utilizing rodent models of depression have shown that direct 
administration of BDNF can alleviate depression-like behavior in these models within minutes 
following administration (Siuciak, et al., 1997).  
In addition to conventional antidepressants effect on BDNF, monoaminergic 
antidepressants have also been shown to modulate the expression of specific glutamate receptors. 
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Two studies by Barbon and colleagues examine the effects of conventional antidepressants on 
glutamatergic 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propionic acid (AMPA) receptor 
expression.  In 2006, Barbon and colleagues found that after 14 days of treatment with either the 
SSRI fluoxetine or the SNRI reboxetine, rat hippocampal and prefrontal cortex (PFC) samples 
showed increases in AMPA receptor mRNA (Barbon et al., 2006).  In a 2011 follow-up time 
course study, Barbon and colleagues examined the effect of chronic administration of classic 
antidepressants on the number of expressed AMPA receptors. However, in this study rodent 
hippocampal and PFC samples were collected at multiple time points over a two week period 
from animals treated with either fluoxetine or reboxetine and were analyzed for AMPA receptor 
mRNA. The researchers found non-significant increases in AMPA receptor mRNA was achieved 
after one week of treatment and significant, and maximal, AMPA receptor mRNA upregulation 
was achieved after 14 days of treatment (Barbon et al., 2011).  This finding is incredibly 
important as the time-course for depressive symptom relief under chronic (daily) administration 
of typical antidepressants is four to six weeks. The studies by Barbon et al., demonstrate that 
chronic administration of typical antidepressants increases the number of receptors of a 
completely different neurotransmitter system, the glutamate system, and implicate the glutamate 
system as a possible mediator of their antidepressant effects.  
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2.3: The Role of Glutamate in MDD 
 
 
 
  Glutamate is the major excitatory neurotransmitter in the nervous system and it plays a 
major role in learning and memory, neurogenesis, synaptogenesis, and neuronal survival 
(Matteson, 2008). Glutamatergic neurons are located throughout the brain with high 
concentrations found in the cerebral cortex, amygdala, hippocampus, and cerebellum, among 
others, which project to numerous subcortical structures such as the striatum, thalamus, some 
limbic system structures, and areas in the brainstem. There are two distinct classes of glutamate 
receptors, ionotropic and metabotropic, and each class has multiple receptor subtypes.  The 
ionotropic family consists of kainate, N-methyl D-aspartate (NMDA), and 2-amino-3-(5-methyl-
3-oxo-1,2- oxazol-4-yl) propanoic acid (AMPA) receptors.  There are 8 metabotropic glutamate 
receptors (mGluRs; labeled 1 through 8) that are sub-divided into 3 individual families based on 
functionality and location.   
There is a growing body of evidence implicating that the glutamatergic system plays a 
role in the neurobiology of MDD. Several studies have reported increased glutamate levels in 
blood and cerebrospinal fluid (CSF) of patients suffering from MDD (Kim, 1982; Altamura et 
al., 1993; Mauri, 1998; Mitani et al., 2006).  Mitani and colleagues also reported a positive 
correlation between plasma glutamate levels and the severity of symptoms in patients with MDD 
(Mitani et al., 2006).  Furthermore, increased levels of glutamate have been reported in the 
frontal cortex of postmortem brain samples from MDD patients (Hashimoto, Sawa, Iyo, 2007b), 
and an in vivo study using magnetic resonance spectroscopy (MRS) revealed elevated levels of 
glutamate in the occipital cortex of MDD patients (Sancora et al., 2004a).  However, numerous 
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studies using MRS have reported contrasting findings of decreased levels of glutamate and its 
precursor glutamine in the anterior cingulate cortex, prefrontal cortex, and hippocampus of MDD 
patients (Auer et al., 2000; Ajilore et al., 2007; Hasler et al., 2007; Block et al., 2009).  
Postmortem studies of brain samples from MDD patients show decreased levels of glutamate 
NMDA receptor subtypes, AMPA receptor subtypes, and one metabotropic glutamate receptor 
(mGluR5) in various brain regions such as the superior temporal cortex, perirhinal cortex, 
hippocampus, and prefrontal cortex (Nudmam-Thanoi, 2004; Beneyto et al., 2007; Law, Deakin, 
2001; Feyissa et al., 2009).  When combined, these findings suggest that alterations in glutamate 
levels play a role in the pathophysiology of MDD. 
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2.4: Glutamate and Neurogenic Processes 
 
In 1966, Terje Lomo discovered that repeated high frequency stimulation of 
glutamatergic neurons via microelectrodes in the hippocampal perforant path lead to prolonged 
excitation of cells in the dentate gyrus (Lomo, 1966).  Follow-up experiments demonstrated that 
stimulation of the perforant path led to a state of increased excitability of cells in the dentate 
gyrus lasting for up to 10 hours post stimulation (Bliss and Lomo, 1973). This long lasting 
excitability was termed long-term potentiation, or LTP. Further investigations demonstrated that 
LTP consists of two stages: an early and a late stage, and that NMDA receptor activation is 
required for the development of both types of LTP (Collingridge et al., 1983; Harris et al., 1984).  
Early LTP encompasses local changes occurring within a pre-existing synapse while late LTP 
involves the stimulation of intracellular pathways that promote the growth of new synapses 
(synaptogenesis) and completely new neurons (neurogenesis). Electrical stimulation of neurons 
in the perforant path causes them to release glutamate into their synaptic connections with cells 
in the dentate gyrus. Synaptic glutamate acts upon both AMPA and NMDA receptors on the 
post-synaptic cell and co-activation of these receptors results in an excitatory post-synaptic 
potential (EPSP) which triggers the production and expression of even more AMPA receptors. In 
1999, Shi and colleagues demonstrated that this increase in the number of AMPA receptors 
expressed into the synaptic space strengthens the synaptic connection between the pre-synaptic 
and post-synaptic cells. More importantly, Shi and colleagues demonstrated that NMDA receptor 
activation is a pre-requirement for increased AMPA receptor activation in that administration of 
the NMDA receptor antagonist (D,L)-2-amino-5-phosphono valeric acid (AP-5) prior to 
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neuronal stimulation prevented the increased expression of AMPA receptors (Shi et al., 1999). 
This strengthening of the local synapse through AMPA receptor up-regulation via NMDA 
receptor activation is the mechanistic process of early LTP. While early LTP is confined to the 
local production of new AMPA receptors, late LTP involves activation of internal protein 
pathways which stimulate the synthesis of new proteins called growth factors, such as BDNF. 
Once released into the synapse, these growth factors trigger the production of new dendritic 
spines on post-synaptic cells and new axon terminals on pre-synaptic cells (Nägerl et al., 2007).  
Frey and colleagues demonstrated that administration of drugs that prevent the synthesis of these 
growth factors prevent the induction of late LTP (Frey et al., 1988).  
In his Croonian Lecture, Santiago Ramon y Cajal suggested that memories may be 
formed by the strengthening of communication between already connected neurons (Cajal, 
1894). If the processes of glutamatergic NMDA receptor activation and additional AMPA 
receptor expression seen in LTP are the underlying biological mechanisms of learning and 
memory, then it would follow that antagonism of one of these receptors should impair and/or 
prevent these processes. As NMDA receptor activation is the initial step in LTP, then it makes 
the most logical target to test this theory. In 1986, Morris and colleagues administered the 
NMDA antagonist AP-5 to rodents exposed to spatial memory task (the Morris Water Maze, 
Morris, 1984) and found that the pharmacological blockade of NMDA receptors impaired 
performance, as measured by increased time of performance, compared to control animals 
(Morris et al., 1986). Since the study published by Morris, there have been numerous subsequent 
studies demonstrating that NMDA receptor blockade impairs learning in a variety of memory 
tasks (Danysz et al., 1988; Butelman E., 1989). Furthermore, mice with increased NMDA 
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receptor expression via genetic manipulation have demonstrated increased capacity for learning 
and memory (Tang et al., 1999) highlighting this receptor’s role in these processes.    
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2.5: Research into Glutamate, Neurogenesis, and Depression 
 
 
 
Early animal models of depression centered on producing a depressive phenotype 
utilizing rodents. That is, producing a behavioral pattern analogous to depressive symptoms seen 
in humans.  Paradigms such as the forced-swim test (FST) (Porsolt, 1977), the tail-suspension 
test (TST) (Steru et al., 1985), and inescapable shock paradigm (Seligman & Beagley, 1975) 
became the standard pre-clinical depression models used to evaluate novel antidepressants. The 
common manipulation in these models involves exposing the animal to an inescapable stressor 
resulting in a reduction in behavioral activity, which is referred to as a state of learned 
helplessness or behavioral despair.  In these preclinical rodent models, compounds that are able 
to reduce immobility (i.e. attenuate behavioral despair) are deemed to have antidepressant 
effects. 
 As early depression models attempted to create a state of learned helplessness and given 
the role of glutamatergic NMDA receptors in learning, it would follow that antagonism of this 
receptor may prevent the onset of learned helplessness. Following this hypothesis, Trullas and 
Skolnick evaluated two NMDA receptor antagonists, AP-7 (2-amino-7-phosphonoheptanoic 
acid) and MK-801 (Dizocilpine) in the FST. Both compounds were found to attenuate the 
depressive phenotypes (i.e. reduce immobility) in this model equal to the effects of the tricyclic 
antidepressant imipramine (Trullas and Skolnick, 1990).  Since this initial investigation there 
have been numerous studies replicating these results and evaluating the efficacy of other NMDA 
antagonists in preclinical rodent models of depression. Two subsequent studies investigating 
MK-801 demonstrated antidepressant effects in in a chronic mild stress (CMS) paradigm (Papp 
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and Moryl, 1994) and again in the FST (Maj et al., 1992). However, MK-801’s antidepressant 
effects have not been evaluated in clinical trials due to its numerous undesirable side effects such 
as cognitive disruptions, psychotic-spectrum disorders, and the induction of brain lesions, 
referred to as Olney’s lesions. Another NMDA antagonist, memantine, has also demonstrated 
antidepressant effects in rodent models of depression (Reus et al., 2010, Quan et al., 2011). 
However, other research has produced opposing findings with memantine in that it failed to 
produce antidepressant effects in the rodent FST and the newer novelty-suppressed feeding 
paradigm (Gideons et al., 2014). In line with these latter findings, clinical trials with memantine 
failed to demonstrate any antidepressant effects in both unipolar (Zarate et al., 2006b) and 
bipolar depressive patients (Anand et al., 2012).   
 More recent research has identified another NMDA antagonist, ketamine, as a potential 
novel and fast acting antidepressant. Ketamine is a synthetic compound, high doses of which 
have long been known to produce dissociative effects and anesthesia. As such, ketamine has 
been used as a general pre-surgery anesthetic (Domino, E., Chodoff, P., Corssen, G., 1965, 
Corssen, G., Miyasaka, M., Domino E., 1968). Pre-clinical animal models of depression have 
demonstrated ketamine’s antidepressant effects (Sufka et al, 2009; Chaturvedi, Chandra, Bapna, 
1999; Yilmaz et al., 2002).  In addition to its success in animal models, ketamine has also 
demonstrated antidepressant effects in clinical trials with MDD sufferers (Berman et al., 2000).  
Furthermore, in a 2006 study in TRD patients, a single sub-anesthetic dose of ketamine 
demonstrated antidepressant effects as early as 2 hours after administration. The same study 
found that after 24 hours, 71% of the patients reported depressive symptom improvement, and 
these antidepressant effects of this one time administration were sustained for more than a week 
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(Zarate, 2006a).  This finding of ketamine’s antidepressant effects in TRD sufferers specifically 
has been replicated in another, more recent, clinical trial (Price et al., 2009). However, despite 
these promising findings, ketamine is structurally similar to phencyclidine (PCP) and produces a 
similar dissociative state, hallucinations, and euphoria, and possess abuse/addictive potential 
(Siegel, 1978), making it an unlikely candidate for long-term use in the clinical treatment of 
depressive disorders. Additionally, given the NMDA receptor’s role in learning and memory, an 
investigation into the cognitive effects of ketamine administration in TRD patients found that 
after an intravenous infusion of 0.5 mg/kg dose of ketamine, patients showed cognitive 
impairments as measured by scores on a battery of cognitive tests including intelligence quotient 
(IQ) tests and the MATRICS Consensus Cognitive Battery test (Murrough et al., 2013).  Yet, the 
preclinical and clinical findings with ketamine are promising and prompted research on other 
glutamatergic targets.  
 The two glutamatergic receptors NMDA and AMPA are co-localized on the post-
synaptic dendritic spine and, as such, co-activate upon the release and binding of the 
neurotransmitter glutamate. Therefore, probing the nearby AMPA receptor for antidepressant 
effects was the first and most obvious glutamatergic candidate. A study in 2001 by Li and 
colleagues measured the antidepressant effects of the AMPA receptor potentiator LY392098 in 
the rodent FST and TST. Acting similarly to a true agonist, a receptor potentiator increases 
activity at receptor; however, a potentiator requires the presence and activation of the receptor by 
the parent neurotransmitter, in this case glutamate. When both the neurotransmitter and a 
receptor potentiator act at a receptor simultaneously, the potentiator increases the activity at the 
receptor by keeping the ion channel open longer, allowing for greater excitement of the post-
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synaptic neuron.  Li and colleagues found that LY392098 attenuated behavioral despair (i.e. 
possess antidepressant effects) in both models.  Furthermore, pre-treatment with an AMPA 
receptor antagonist, LY300168, blocked the antidepressant effects of LY392098 (Li et al., 2001). 
In 2008, Maeng and colleagues investigated the relationship between NMDA and AMPA 
receptors and demonstrated that AMPA receptor activation is required for ketamine’s 
antidepressant effect.  In this study, the researchers first administered the AMPA receptor 
antagonist NBQX prior to the administration of ketamine to rodents prior to exposure to the FST 
and found that pre-treatment with NBQX prevented ketamine’s antidepressant effects (Maeng et 
al., 2008). These findings suggest that activation of the glutamatergic AMPA receptor is the true 
mechanism that provides antidepressant effects.  
 Research from Li and colleagues proposes the exact pathway and methodology of how 
AMPA receptor activation leads to an antidepressant response. Since it is well accepted that 
AMPA receptor activation leads to the promotion of growth factors seen in LTP processes, the 
study examined one of the intracellular protein kinases responsible for the cytoskeletal 
reorganization and branching required in neurogenic processes, the mammalian target of 
rapamycin (mTOR).  The researchers hypothesized that since ketamine exerts its antidepressant 
effects through AMPA receptor activation leading to LTP processes of synaptogenesis and 
neurogenesis, that a pharmacological inhibition or blockade of the mTOR protein might prevent 
ketamine’s antidepressant effects. In a drug challenge study, Li and colleagues inhibited the 
mTOR pathway with the protein antagonist rapamycin prior to the administration of ketamine in 
animals tested in the FST. The pre-treatment with rapamycin prevented ketamine from 
demonstrating antidepressant effects in the model (Li et al., 2010).  While inhibition of the 
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mTOR pathway via rapamycin does provide us with an understanding of how ketamine might 
indirectly provide its antidepressant effects, it does not answer the question of how ketamine, an 
NMDA receptor antagonist, would potentiate or activate the nearby AMPA receptor.  
 More recent research performed in collaboration from various institutes including the 
National Institute of Mental Health (NIMH) has provided a possible answer to this question. 
There are numerous metabolites produced from the enzymatic breakdown of ketamine, and prior 
research has demonstrated that only ketamine and its metabolite (R,S) norketamine produce 
anesthesia, although (R,S) norketamine is less potent.  Other ketamine metabolites fail to 
produce any level of anesthesia, and as such, were thought to be biologically inactive. In an 
extensive 2016 study, Zanos and colleagues examined the mechanisms behind ketamine’s 
antidepressant effects, and included all of ketamine’s metabolites. First, they evaluated the 
antidepressant effects of the NMDA antagonist ketamine compared to the tricyclic antidepressant 
desimipramine at time points of 1-hour post drug administration and again at 24 hours post drug 
administration. The researchers found that both desimipramine and ketamine demonstrated 
antidepressant effects at the 1 hour mark, but only ketamine exhibited antidepressant effects at 
the 24 hour mark. These findings are consistent with other preclinical findings and with the 
clinical effects of ketamine’s anti-depressant effects.  Furthermore, the researchers demonstrated 
that the NMDA antagonist MK-801 produced antidepressant effects at the 1 hour mark, but 
failed to produce antidepressant effects at the 24 hour mark in the FST. These findings led the 
researchers to hypothesize that NMDA receptor antagonism may not be the mechanism behind 
ketamine’s antidepressant effects. The researchers then evaluated the antidepressant effects of a 
number of ketamine’s metabolites. Through evaluation in the FST, the researchers showed that 
  
27 
 
similar to ketamine, a single administration of one ketamine metabolite, (2R,6R)-
hydronorketamine (HNK), induced persistent antidepressant effects lasting for at least 3 days of 
testing in the FST. However, unlike ketamine, HNK did not displace MK-801 at the NMDA 
receptor, suggesting that its mechanism of behavioral effects lies elsewhere. The researchers then 
showed that HNK facilitates AMPA receptor activity via an increase in frequency and amplitude 
of AMPA receptor excitatory potentials. Next the researchers sought to determine if AMPA 
receptor activation is required in HNK’s antidepressant effects by performing a challenge study 
wherein animals were pretreated with the AMPA antagonist NBQX prior to either ketamine or 
HNK administration then evaluated in the FST.  In line with research mentioned earlier, 
pretreatment with NBQX prevented ketamine’s antidepressant effects. Furthermore, pre-
treatment with NBQX also prevented HNK’s antidepressant effects seen at both the 1 hour and 
24 hour mark. As it has been implied that ketamine’s antidepressant effects are mediated through 
both the activation of the mTOR protein and increased BDNF production, the researchers sought 
to determine if HNK also increases activity or levels of these separate proteins. Interestingly, the 
study showed that neither ketamine nor HNK produced increased activity in the mTOR protein 
in hippocampal and prefrontal cortex tissue samples. However, both ketamine and HNK 
increased hippocampal BDNF production. The researchers then demonstrated that both ketamine 
and HNK produce increases in AMPA receptor expression 24 hours after administration. 
Moreover, HNK’s antidepressant effects remained long after the time point where HNK was 
undetectable in select brain tissue samples, suggesting its antidepressant effects are the result of 
long-lasting synaptic changes as seen in LTP (Zanos et al., 2016). 
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2.6 Converging Lines of Evidence 
 
 A quick summary of the numerous lines of research discussed so far is necessary. Firstly, 
separate research has demonstrated that traditional monoaminergic antidepressants induce the 
production of the growth factor BDNF and that chronic administration of these compounds also 
increases the expression of glutamatergic AMPA receptors and do so in a time-course that 
resembles their antidepressant effects. Secondly, direct administration of BDNF has 
demonstrated antidepressant effects in pre-clinical models of depression. Thirdly, numerous 
clinical studies have detected glutamatergic alterations in MDD patients implying a role for 
glutamate in the etiopathology of MDD. Finally, pharmacological potentiation of the 
glutamatergic AMPA receptor has demonstrated antidepressant effects in pre-clinical models of 
depression and pharmacological antagonism of the glutamatergic NMDA receptor via ketamine 
has demonstrated antidepressant effects in both pre-clinical models and in a number of clinical 
trials for both MDD, TRD, and bi-polar patients. Furthermore, pre-clinical studies have 
demonstrated that AMPA receptor activation is required for ketamine’s antidepressant effects.  
 Combining these lines of research, a conclusion can be drawn that explains exactly how 
monoaminergic antidepressants and ketamine produce their therapeutic effects. Chronic 
administration of traditional antidepressants that target the monoaminergic system result in 
increased expression of more AMPA receptors far downstream in the glutamatergic system, and 
by doing so, allow for greater glutamate-AMPA receptor activity which stimulates the 
underlying processes seen in LTP, such as production of and release of growth factors, namely 
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BDNF. A number of studies have indicated that decreased levels of BDNF are associated with 
MDD and that BDNF levels increase following antidepressant pharmacotherapy. (Duman and 
Monteggia, 2006; Martinowich et al., 2007). Synaptic BDNF acts on both pre- and post-synaptic 
tyrosine receptor kinase B (Trk-B) receptors and stimulate the mTOR protein pathway 
responsible for cytoskeletal growth of new dendritic branches and axon terminals 
(synaptogenesis), eventually leading to the growth of new neurons (neurogenesis). The resulting 
increase in neuronal plasticity offsets the losses caused by stress-induced release of hormones. 
However, more evidence is needed before concluding that these neuroplastic changes are the 
underlying mechanisms behind the antidepressant effects seen across multiple 
pharmacotherapies.   
 As mentioned in the earlier sections of this paper, prior to the discovery of the 
hydrazines, outside of psychotherapy, the primary treatment method for depression was electro-
convulsive shock therapy. While its biological effects were not understood at the time, advances 
in science have allowed for closer examinations. Numerous studies have examined the 
relationship and effect of ECT and biological alterations, specifically, changes to BDNF 
production. In a systematic review and meta-analysis of both pre-clinical and clinical studies 
investigating the effect of ECT on BDNF, Polyakova and colleagues found that animal and 
human studies report similar findings in regard to effects of ECT on BDNF; that is, that ECT 
increases brain BDNF in both preclinical and clinical studies. Moreover, multiple treatments 
with ECT, compared to a single ECT treatment, were associated with larger increases in BDNF 
in both animals and humans. These findings suggest that a dose-response relationship exists 
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between the schedule of ECT and BDNF increases (Polyakova M., et al., 2015) and that 
neuroplastic process are responsible for the antidepressant effects of ECT.   
 Though ECT may be an effective treatment option, it is generally a method of last resort 
in depressed patients who have failed to respond to both pharmacotherapies and psychotherapies. 
There are a variety of psychotherapies that have been employed to treat MDD including (but not 
limited to) interpersonal therapy (IPT) and cognitive-behavioral therapy (CBT).  Recent studies 
have investigated the effects of such psychotherapies on the activity, volumetric size, and rate of 
metabolism in key brain structures associated with MDD. Neuroimaging of MDD patients 
reveals a decrease in activity and metabolism of cells within the dorsolateral prefrontal cortex 
(DLPFC), which is correlated with depressive symptom severity (Brody et al., 2001). The 
DLPFC is involved in executive functions such as working memory, cognitive flexibility, 
planning, reasoning, and behavioral inhibition. On a note of interest, the main neurotransmitters 
involved in DLPFC functioning are glutamate, dopamine, norepinephrine, and acetylcholine, 
with very little serotonin activity. This may explain why some MDD patients fail to show 
symptom relief with typical antidepressants designed to increase serotonin activity.  A review by 
Frewen and colleagues in 2008 found within therapy responders that both IPT and CBT restored 
normal functioning of the DLPFC as measured by both rates of activity and metabolism (Frewen 
et al., 2008). Frewen and colleagues also reported that the increased activity in DLPFC remained 
long after the conclusion of therapy, findings resembling the effects of electrical stimulation and 
the discovery of LTP process in the hippocampus by Bliss and Lomo mentioned earlier. 
Furthermore, cognitive therapy has been demonstrated to increase the volume of grey matter in 
the DLPFC (Seminowicz et al., 2013). Similarly, a study by Straub and colleagues found 
  
31 
 
increases in hippocampal activity in MDD patients following CBT (Straub et al., 2015), and a 
2013 study by Moustafa reported increases in volumetric size of the hippocampus following 12 
weeks of CBT (Moustafa, 2013). Together, these findings suggest that the various forms of 
psychotherapy increase activity and volume of key brain structures involved in MDD, although 
BDNF levels have not been directly measured, the increases in these measures implies the role 
neuroplastic processes play in the benefits of psychotherapy. 
 Individuals suffering from MDD have provided anecdotal evidence suggesting that 
physical exercise can alleviate depressive symptoms. And indeed, in a meta-analysis of 
numerous scientific studies investigating such a relationship, Craft and Perna reported that 
response rates in antidepressant-naïve MDD patients who engaged in moderate to high physical 
exercise is slightly higher (approximately 70%-80%) on overage than patients taking 
antidepressant pharmacotherapies alone (Craft and Perna, 2004). Subsequent studies have 
demonstrated that exercise leads to an increase in BDNF production, particularly in the 
hippocampus (Cotman et al., 2007), and this increase promotes improvement in cognitive 
functioning and MDD symptoms (Marais et al., 2009; Russo-Neustadt et al., 2000). Again, these 
findings in the effects of exercise suggest that neuroplastic changes underlie the benefits of 
exercise in treating depression. 
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3.0: CONCLUSION: THE STRESS-NEUROGENIC THEORY OF DEPRESSION 
 
The purpose of this paper was to examine the discovery of the monoamine theory of 
depression, evaluate its validity, and compare alternative treatment modalities in hopes of 
identifying common biological effects.  While the monoamine theory remains the dominant 
explanatory model of MDD, the issues with its discovery and the shortcomings of 
monoaminergic antidepressants listed above bring into question its validity.  The measureable 
downstream effects of conventional antidepressants on increased BDNF and up-regulation of 
AMPA receptors suggest the true mechanism of monoaminergic antidepressants may not be the 
direct elevation of synaptic monoamine levels. In short, I suggest that the Monoamine Theory of 
MDD is incomplete.  
 There is mounting evidence for an alternative explanatory model for the etiopathology of 
MDD, the Stress-Neurogenic Theory. This theory posits that unpredictable stress induces the 
production of stress hormones that lead to neuronal death in key brain structures, such as the 
hippocampus and amygdala, and this cell loss is responsible for the onset of MDD 
symptomology.  Psychological stress activates the release of a stress hormone from the 
hypothalamus called corticotrophin-releasing hormone (CRH), which stimulates the pituitary 
gland to release corticotrophin that then stimulates the adrenal gland to release cortisol.  
Evidence of CRH’s role in the pathology of MDD can be found in elevated levels of CRH in the 
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cerebrospinal fluid of MDD patients (Nemeroff, Widerlov, Bissette, 1984) as well as post-
mortem studies that have found increased numbers of CRH releasing neurons in the limbic 
system structures in MDD patients (Raadsheer, Hoogendijk, Stam, 1994).  Excessive levels of 
cortisol can cause decreased neurogenesis, neurotoxicity, and neuronal cell death. It is believed 
that repeated exposure to psychosocial stressors leads to over stimulation of the HPA-axis 
resulting in increased levels of glucocorticoids. This increase in stress hormones is responsible 
for the decrease in brain structure volume seen in the post-mortem studies of MDD patients. 
Furthermore, the Stress-Neurogenic theory suggests that MDD can be treated by stimulating 
synaptogenesis and neurogenesis in these structures, thus offsetting the neuronal loss due to 
repeated over-exposure to stress hormones.  
 Evidence in support of this theory can be seen in all of the various treatment forms that 
have efficacy in treating MDD. Typical monoaminergic antidepressants, ketamine and other 
glutamatergic agents, ECT, various forms of psychotherapy, and even exercise have all 
demonstrated the ability to increase either neurotrophic growth factors, such as BDNF, or 
structural volume in key brain regions affected by excess stress hormones. By identifying this 
commonality among the various treatment modalities, it is this author’s hope that by targeting 
the brain’s natural neurogenic pathways, newer and faster acting antidepressants can be 
identified for use in treating this debilitating disorder.  
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